LLY vs MRK
Eli Lilly and Merck & Co., both Healthcare
Eli Lilly is the larger company at $1.2T against $358B. On trailing earnings LLY is the cheaper of the two at a P/E of 42.8 against 115.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +77% against +56% for LLY. The RyuScore puts MRK ahead, 76 against 60 out of 100.
| Figure | LLY | MRK |
|---|---|---|
| Last close | $1274 | $145 |
| Market cap | $1.2T | $358B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.8 | 115.3 |
| Dividend yield | 0.5% | 2.2% |
| 1-year return | +56% | +77% |
| 5-year return | +470% | +111% |
| RyuScoresector-relative, 1–10 | 60/100 | 76/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Eli Lilly
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.